Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2009

View Archived Issues

Further results from ongoing phase I study of AC-220 show benefit in AML patients

AFP-464 synergistic with vorinostat in breast cancer cells

I-PRESERVE finds no benefit of irbesartan in heart failure with preserved ejection fraction

GlaxoSmithKline reports on discovery of EP1 receptor antagonist for inflammatory pain

Chalcone derivative blocks Abeta impairment of PKA/CREB signaling

Endo to acquire Indevus

EMEA accepts Cerepro Marketing Authorization Application for review

FDA lifts hold on Advaxis' phase II cervical intraepithelial neoplasia trial

Chimerix completes phase I and initiates phase II multidose trial for CMX-001

Genta summarizes phase II activity and receives orphan drug status for tesetaxel

Kythera reports positive phase II results for ATX-101 in submental fat reduction

YM's nimotuzumab to be evaluated in phase II and III trials for cancer

Phase III trial starts for GammaGard Liquid in primary immunodeficiency

CHMP recommends orphan drug status for ARG-201 in systemic sclerosis

Cubist submits two INDs targeting serious infections

Cytochroma commences phase I CTAP-201 injection in chronic kidney disease

Cylene initiates phase I trial with CK2 protein kinase inhibitor, CX-4945

ChemoCentryx divulges new chemokine CCR1 receptor antagonists for immune disorders

BioMarin and La Jolla enter worldwide agreement for Riquent

Novel DGAT-1 inhibitors discovered by Janssen researchers

GSK scientists describe new AMPA receptor agonists in recent patent

CureVac receives FDA IND approval for phase I/IIa mRNA vaccine trial

Novel ghrelin receptor ligands under development at GSK for treatment of obesity

Bayer Schering Pharma submits Visanne for registration in Europe for endometriosis

New antibacterial agents reported in recent Meiji Seika patent

Emergent BioSolutions ends activities to acquire Protein Sciences

UCB receives FDA complete response letter for Cimzia in RA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...